Aleksandr Urtikov

Mr. Aleksandr Urtikov

FSBI "National Medical Research Center for Phthisiopulmonology and Infectious Diseases" of the Ministry of Health of the Russian Federation, Moscow, Moskva, Russia
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 December 2022 in Pathogens
Verified
Journal Article
Open access
PDF file
NPNikolay Pimenov
Nikolay Pimenov
DKDmitry Kostyushev
Dmitry Kostyushev
SKSvetlana Komarova
Svetlana Komarova
AFAnastasia Fomicheva
Anastasia Fomicheva
AUAleksandr Urtikov
Aleksandr Urtikov
Vladimir ChulanovVladimir Chulanov
Vladimir Chulanov
The hepatitis C virus (HCV) causes both acute and chronic infection of the liver that can lead to liver cirrhosis, cancer, and liver failure. HCV is characterized by high genetic diversity and substantial variations in the prevalence of specific HCV genotypes throughout the world. Many effective regimens of direct-acting antivirals (DAAs), including pan-genotypic, can successfully treat HCV infection. Additionally, genotype-specific treatments for HCV are being actively employed in national plans for eliminating HCV infection around the world. The evaluation of HCV genotype prevalence in a given country is necessary for the successful implementation of the HCV elimination plans and for allocating financial resources to the DAAs which are the most effective against those specific HCV genotypes prevalent in a given country. Here, we analyzed HCV genotypes, subgenotypes, and recombinants in 10,107 serum samples collected in 2015–2017 from patients with chronic HCV infection living in all federal districts of Russia. This is the first and largest evaluation of HCV genotypes performed on samples from all territories of Russia, from its Central federal district to the Far East. Moreover, we have updated retrospective epidemiological analysis of chronic and acute HCV infection in Russia from 2001 to 2021. We demonstrate that the incidence of acute HCV (AHC) infection in Russia decreased from 16.7 cases per 100,000 people in 2001 to 0.6/100,000 in 2021. The number of cases of chronic HCV (CHC) infection also decreased from 29.5 to 16.4 per 100,000 people during this period. The HCV genotype analysis indicated that HCV genotype 1 dominates in Russia (53.6%), while genotypes 3 and 2 were detected in 35.4% and 7.8% of patients, respectively. These proportions are virtually identical in all regions of Russia except for the Far East, where HCV genotype 2 was detected in only 1% of the samples. HCV genotypes 1 and 2 are more widespread in women, and HCV genotype 3 in men. Genotype 3 was the most prevalent in 31–40-year-olds (44.9%), and genotype 1 was most prevalent in those over 70 years of age (72.2%). HCV genotype 2 was predominant among HCV-infected persons older than 40 years. Discriminating between HCV genotype 2 and recombinant RF1_2k/1b, which are frequently misclassified, is important for successful antiviral treatment. For the first time, we demonstrate, here, countrywide prevalence of HCV RF1_2k/1b in different regions of Russia. HCV RF1_2k/1b makes up 3.2% of HCV genotypes, reaching 30% among samples classified as genotype 2 by some commercial genotyping tests. The highest proportion of HCV RF1_2k/1b was detected in the North-West (60%), Southern (41.6%), and Central (31.6%) federal districts; its frequency in the Far Eastern and North Caucasus districts was ~14.3%. HCV RF1_2k/1b, and it was not detected in the Volga, Ural, or Siberian districts. To conclude, this is the first and most complete evaluation of HCV epidemiology and genotype/subgenotype distribution in Russia.

2 November 2022 in Preprints.org
Verified
Preprint
Open access
PDF file
NPNikolay Pimenov
Nikolay Pimenov
DKDmitry Kostyushev
Dmitry Kostyushev
SKSvetlana Komarova
Svetlana Komarova
AFAnastasia Fomicheva
Anastasia Fomicheva
AUAleksandr Urtikov
Aleksandr Urtikov
Vladimir ChulanovVladimir Chulanov
Vladimir Chulanov
Hepatitis C virus (HCV) causes both acute and chronic disease of the liver that can lead to liver cirrhosis, cancer and liver failure. HCV is characterized by high genetic diversity and substantial variations in prevalence of specific HCV genotypes in different countries of the world. Many effective regimens of direct-acting antivirals (DAAs), including pan-genotypic, can successfully treat HCV infection. However, genotype-specific treatments for HCV are being actively employed in the national plans for elimination of HCV infection around the world. Evaluation of HCV genotype prevalence in a country is mandatory for successful implementation of the national plans for elimination of HCV infection and allocation of financial resources to DAAs most effecting for specific HCV genotypes prevalent in a country. Here, we analyzed HCV genotypes, subgenotypes and recombinants in 10,107 serum samples from patients with chronic HCV infection from all Federal districts of Russia collected in 2015-2017. This is the first, largest evaluation of HCV genotypes performed on samples from all territories of Russia, from its Central Federal district to the Far East. Moreover, we have updated retrospective epidemiological analysis of chronic and acute HCV infection in Russia in 2001-2021. We demonstrate that the incidence of acute HCV infection in Russia reduced from 16.7 cases per 100,000 population in 2001 to 0.6 cases per 100,000 population in 2021. The number of cases of chronic HCV infection decreased from 29.5 to 16.4 per 100,000 population during this period. HCV genotype analysis indicated that HCV genotype 1 dominates in Russia (53.6%). Genotypes 3 and 2 were detected in 35.4% and 7.8% of patients respectively. These proportions are virtually identical in all regions of Russia except for Far East, where HCV genotype 2 amounts only to 1%. HCV genotypes 1 and 2 are more widespread in women, while HCV genotype 3 in men. The highest frequency of identification of genotype 3 was found in the age group of 31-40 years old (44.9%, respectively), and genotype 1 was more prevalent in a group of over 70 years old (72.2%). The proportion of HCV genotype 2 is predominant among HCV-infected persons older than 40 years. Discriminating HCV genotype 2 and recombinant RF1_2k/1b, which are frequently misclassified, is important for successful antiviral treatment of such patients. For the first time, we demonstrate the countrywide prevalence of HCV RF1_2k/1b in different regions of Russia. HCV RF1_2k/1b amounts to 3.2% in the structure of HCV genotypes, reaching 30% among samples classified as genotype 2 by some commercial genotyping tests. The highest proportion of HCV RF1_2k/1b was detected in the north-west (60%), southern (41.6%) and central (31.6%) federal district. Its frequency in Far Eastern and North Caucasus Districts was ~ 14.3%. HCV RF1_2k/1b was not detected in the Volga, Ural and Siberian districts. To conclude, this is the first and most complete evaluation of HCV epidemiology and genotype/subgenotype distribution in Russia.

15 November 2020 in Epidemiology and Infectious Diseases
Verified
Journal Article
Open access
PDF file
AFAnastasia A. Fomicheva
Anastasia A. Fomicheva
NPNikolay Pimenov
Nikolay Pimenov
SKSvetlana V. Komarova
Svetlana V. Komarova
AUAleksandr Urtikov
Aleksandr Urtikov
OPOlga A. Paevskaya
Olga A. Paevskaya
ЦНЦапкова Наталья
Цапкова Наталья
BACKGROUND: Hepatitis B is an urgent medical and social problem in Russia. AIM: To determine the epidemiological features of the hepatitis B in the Russian Arctic. MATERIALS AND METHODS: We carried out a retrospective analysis of the incidence of hepatitis B (acute and chronic forms) in 9 Russian Arctic regions, 3 subarctic regions (Khanty-Mansiysk Autonomous Okrug, Magadan Region, Kamchatka Territory) and Russian Federation in 19992019. We also studied the prevalence of chronic hepatitis B and vaccination data against hepatitis B in these territories. RESULTS: From 1999 to 2019 the incidence of acute hepatitis B in three subarctic regions decreased 166 times (from 66.5 to 0.4 per 100 thousand population), in the Arctic zone of 74.5 times (from 29.8 to 0.4 per 100 thousand population) and 73 times in Russia (from 43.8 to 0.6). The incidence of chronic hepatitis forms in the same period in the Arctic zone decreased by 8.6 times (from 140.1 to 16.3), 5.8 times in the subarctic regions (from 116.6 to 20.0) and 5.7 times in Russia (from 96.3 to 16.8). In 2018, the results of the prevalence of chronic hepatitis B in the Arctic zone (697.3) was higher than in Russia by 98% (352.1) and higher in the subarctic regions by 67% (588.6). Timely coverage of hepatitis vaccination in children aged 12 months in the Russian Federation, the Arctic zone and the subarctic regions is maintained at a high level (more than 90%) from 2004 in 2019. Coverage of children by vaccination to 17 years inclusive and adults up to 35 years on these territories also exceeded 90%. CONCLUSIONS: Vaccination against hepatitis B in the Russian Federation led to a significant decrease in the incidence of this infection in the Russian Arctic. High prevalence of infection indicates the need to continue the program of mass vaccination and the timely introduction of the first dose of vaccine newborns. To reduce the risk of cirrhosis and liver cancer, it is necessary to increase the availability of diagnosis of the disease and its possible outcomes in the Arctic regions and timely provision of antiviral treatment of all patients.

9 September 2024 in Epidemiology and Vaccinal Prevention
Verified
Journal Article
Open access
PDF file
AFA. A. Fomicheva
A. A. Fomicheva
NPNikolay Pimenov
Nikolay Pimenov
SKS. V. Komarova
S. V. Komarova
AUAleksandr Urtikov
Aleksandr Urtikov
NTN. N. Tsapkova
N. N. Tsapkova
Vladimir ChulanovVladimir Chulanov
Vladimir Chulanov
Aim. To analyze dynamic of incidence and mortality of COVID-19 and clinical and epidemiological characteristics of adult patients with a new coronavirus infection during the early period of the Omicron SARS-COV-2 distribution in Russia. Materials and Methods. We conducted a retrospective analysis of the dynamics of COVID-19 incidence and mortality in Russia until 2023. Study included patients aged ≥18 years with a laboratory-confirmed diagnosis of COVID-19, detected in the period from 01/02/2022 to 14/03/2022 (n = 3 582 688) in 85 regions of Russia. Participants were included regardless their COVID-19 vaccination history. Results. We identified 6 periods of rise and decline in the COVID-19 incidence until 2023 in Russia. The 5th (January–July 2022) and the 6th (August-November 2022) periods were associated with the spread of the Omicron SARS-CoV-2. The median age of patients in the early period of Omicron spreading was 49 (36–62) years, 62.7% were women. The largest proportion of patients were represented by the age groups 30–39 and 40–49 years (19.2% each), the lowest – 18–29 years (12.3%). Proportion of patients with mild disease was 90.0%, moderate – 8.5%, severe – 0.9%, extremely severe – 0.6%. Hospitalization rate, proportion of patients treated in the intensive care unit and rate of invasive mechanical ventilation were 7.6%, 9.5% and 6.7% respectively. The median period from the onset of symptoms to the diagnosis was 2 (1–3) days, median of duration of the disease was 8 (6-10) days and median duration of hospitalization was 10 (7–14) days. The median age of the deceased patients was 77 (69–84) years, of which 50.8% were women, 72.6% were persons ≥70 years old. One or more concomitant diseases were detected among 8.7% of patients who became ill and 75.8% of those who died. The probability of hospitalization, admission to the ICU, IMV and death in patients with one or more concomitant diseases were 24.5, 3.2, 3.5 and 35.8 times higher, respectively, compared with patients without concomitant diseases. Conclusion. In the early period of the spread of the Omicron variant in Russia, among adult patients with COVID-19, excluding their vaccine history, the frequency of severe and extremely severe forms of infection was 1.5%. The elderly age and the presence of concomitant diseases remained key risk factors for the development of adverse outcomes of the COVID-19

22 September 2024 in Journal Infectology
Verified
Journal Article
Open access
PDF file
AFA. A. Fomicheva
A. A. Fomicheva
NPNikolay Pimenov
Nikolay Pimenov
SKS. V. Komarova
S. V. Komarova
AUAleksandr Urtikov
Aleksandr Urtikov
NTN. N. Tsapkova
N. N. Tsapkova
Vladimir ChulanovVladimir Chulanov
Vladimir Chulanov
Aim: To study the manifestations of the COVID-19 epidemic and the clinical and epidemiological characteristics of adult patients with a new coronavirus infection during the dominance of the Delta SARS-COV-2 in the Russian Federation.Materials and Methods: Study included patients aged ≥18 years with a laboratory-confirmed diagnosis of COVID-19, detected in the period from 09/01/2021 to 11/30/2021 (n= 2 619 298) in 85 Russian regions.Results: There were 2 periods of rise and decline in the COVID-19 incidence and mortality during the spread of the Delta SARS-CoV-2 in Russia: June-September and OctoberDecember 2021 (Wald – Wolfowitz criterion, p<0,05). The median age of patients was 49 [36–63] years, 61,1% were women. Most of patients were 30–39 years old (21,0%), the lowest proportion was among 18–29 years old (12.1%) (p<0,05). Proportion of patients with mild disease was 75,4%, moderate – 18,8%, severe – 3,3%, extremely severe – 2,5% (p<0.05). Hospitalization rate was 23,7%, proportion of patients treated in the intensive care unit was 12.9%, and rate of invasive mechanical ventilation was 9,8%. The median period from the onset of symptoms to the diagnosis was 3 [1-6] days, the duration of the disease and hospitalization was 13,0 [10–16] and 12,0 [9–17] days, respectively. The median age of the deceased patients was 73 [65–82] years, of which 59,1% were women, 61,5% were persons ≥70 years old. The presence of one or more comorbidities was found in 73,9% of deceased patients (OR=17,1; 95% CI: 16,8–17,3).Conclusion: during the period of the spread of the Delta SARS-COV-2 variant in Russia, the number of patients with severe and extremely severe disease among adult patients without taking into account the vaccine history was 5,8%. Old age and the presence of concomitant diseases were key risk factors for adverse outcomes of COVID-19.

3 November 2023
Verified
Book Chapter
Closed access
NPNikolay Pimenov
Nikolay Pimenov
DKDmitry Kostyushev
Dmitry Kostyushev
SKSvetlana Komarova
Svetlana Komarova
AFAnastasia Fomicheva
Anastasia Fomicheva
AUAleksandr Urtikov
Aleksandr Urtikov
Vladimir ChulanovVladimir Chulanov
Vladimir Chulanov
Objective: This chapter aims to evaluate the current epidemiology of HCV infection in Russia and determine the distribution of HCV genotypes and clinically relevant HCV subgenotypes (1a, 1b), as well as recombinant RF1_2k/1b. Introduction: The hepatitis C virus (HCV) creates both acute and chronic liver infections, which can result in cirrhosis, cancer, and liver failure. HCV is characterized by tremendous genetic diversity and significant variations in the incidence of particular HCV genotypes around the world. Several effective regimens of direct-acting antivirals (DAAs), including pan-genotypic DAAs, can successfully cure HCV infection. Furthermore, genotype-specific HCV medicines are being actively used in national initiatives to eliminate HCV infection around the world. The assessment of HCV genotype prevalence in a given country is required for the successful execution of HCV elimination strategies and for allocating financial resources to the DAAs that are most effective against the particular HCV genotypes prevalent in that country. Methods: We performed retrospective epidemiological analysis of chronic and acute HCV infections in Russia from 2001 to 2021. A total 10,107 serum samples collected in 2015–2017 from patients with chronic HCV infection living in all federal districts of Russia were screened for HCV genotypes, subgenotypes, and recombinants using PCR and Sanger analysis. Results: The findings showed that the incidence of acute HCV (AHC) infection in Russia decreased from 16.7 cases per 100,000 people in 2001 to 0.6/100,000 in 2021. During this time, the number of chronic HCV (CHC) infections declined from 29.5 to 16.4 per 100,000 persons. According to the HCV genotyping analysis, HCV genotype 1 predominates in Russia (53.6%), whereas genotypes 3 and 2 were found in 35.4% and 7.8% of patients, respectively. Except for the Far East, where HCV genotype 2 was discovered in barely 1% of the samples, these proportions are nearly equal across Russia. HCV genotypes 1 and 2 are more common in women, while HCV genotype 3 is more common in men. Genotype 3 was most common among 31-40-year-olds (44.9%), while genotype 1 was most common in those over 70 (72.2%). HCV genotype 2 was more common in HCV-infected people above the age of 40. The most HCV RF1_2k/1b was found in the North-West (60%), Southern (41.6%), and Central (31.6%) federal districts, with 14.3% found in the Far Eastern and North Caucasus areas. HCV RF1_2k/1b was not found in the Volga, Ural, or Siberian districts. Conclusions: This is Russia's first and most comprehensive study of HCV epidemiology and genotype/subgenotype distribution.